dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Diéguez Martínez, Nora |
dc.contributor.author | Espinosa Gil, Sergio |
dc.contributor.author | Yoldi, Guillermo |
dc.contributor.author | Megías Roda, Elisabet |
dc.contributor.author | Bolinaga Ayala, Idoia |
dc.contributor.author | Viñas Casas, Maria |
dc.contributor.author | Colas Ortega, Eva |
dc.contributor.author | Lizcano De Vega, Jose Miguel |
dc.date.accessioned | 2022-11-14T13:27:03Z |
dc.date.available | 2022-11-14T13:27:03Z |
dc.date.issued | 2022-09-19 |
dc.identifier.citation | Diéguez-Martínez N, Espinosa-Gil S, Yoldi G, Megías-Roda E, Bolinaga-Ayala I, Viñas-Casas M, et al. The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival. Cell Mol Life Sci. 2022 Sep 19;79:524. |
dc.identifier.issn | 1420-9071 |
dc.identifier.uri | https://hdl.handle.net/11351/8468 |
dc.description | Apoptosi; Càncer d'endometri; Mapa quinasa |
dc.description.sponsorship | Open Access Funding provided by Universitat Autonoma de Barcelona. The JM Lizcano research group was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO, grant SAF2015-64237-R), and the Spanish Ministry of Science and Innovation (grant PID2019-107561RB-I00), and co-funded by the European Regional Development Fund (ERDF). |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Cellular and Molecular Life Sciences;79 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Endometri - Càncer - Tractament |
dc.subject | Endometri - Càncer - Aspectes genètics |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject.mesh | Endometrial Neoplasms |
dc.subject.mesh | /genetics |
dc.subject.mesh | Cell Proliferation |
dc.subject.mesh | Antineoplastic Agents |
dc.title | The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s00018-022-04541-6 |
dc.subject.decs | neoplasias endometriales |
dc.subject.decs | /genética |
dc.subject.decs | proliferación celular |
dc.subject.decs | antineoplásicos |
dc.relation.publishversion | https://doi.org/10.1007/s00018-022-04541-6 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Diéguez-Martínez N, Espinosa-Gil S, Bolinaga-Ayala I, Viñas-Casas M, Lizcano JM] Departament de Bioquímica i Biologia Molecular, Unitat de Medicina, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca en Proteïnes Kinases i Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Yoldi G] Departament de Bioquímica i Biologia Molecular, Unitat de Medicina, Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Megías-Roda E] Grup de Recerca en Proteïnes Kinases i Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Ability Pharmaceuticals, SL. Cerdanyola del Vallès, 08290 Barcelona, Spain. [Colas E] Grup de Recerca Biomèdica en Ginecologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERONC, Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 36123565 |
dc.identifier.wos | 000855462200001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |